anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a feed for fish and shell which contains lower amino acids and higher amino acids at a specific ratio in the matrix material comprising the fermentation product of draining or refuse that remains after plants are strained and improves the food intake efficiency of fish and shell by stimulating the olfaction of fish and shell with the amino acids eluted in water. SOLUTION: The draining or refuse that remains after plants are strained (suitably free from alkaloids other than methylated purine derivative and toxic glycosides) is used to eftect fermentation of a microorganism. To the matrix material containing the fermentation product or its crushed product, are added (A) amino acids of 2-3 carbon atoms such as glycine or α-alanine and (B) amino acids of 4 or more carbon atoms such as leucine, ornithine at a molar ratio A/B of 1-0. The microorganism for fermenting the strained lees is preferably lactic acid bacteria or Saccharomyces yeasts. When a glue is combined with amino acids (A) and (B), they readily adhere to the matrix material desirably. In this case, the components A and B are added to the matrix material in the form of an aqueous solution and the glue is preferably a natural glue.
Effective and safe use of albuterol sulfate inhalation aerosol includes an understanding of the way that it should be administered.

Shake well before each spray.

Use albuterol sulfate inhalation aerosol only with the actuator supplied with the product. Discard the albuterol sulfate inhalation aerosol inhaler when the dose indicator displays 0 or after the expiration date on the product, whichever comes first. Never immerse the canister in water to determine how full the canister is ("float test").

In general, the technique for administering albuterol sulfate inhalation aerosol to children is similar to that for adults. Children should use albuterol sulfate inhalation aerosol under adult supervision, as instructed by the patient's physician.
Importance: Transgender patients who desire a gender-congruent neck contour may forego transcutaneous procedures due to the risk of neck scar stigmata related to such procedures. Objective: To describe the development and experience with the first 77 cases of a novel gasless transvestibular technique for gender-affirming surgery of the laryngeal prominence. Design, Setting, Participants: Video and narrative description of a novel surgical technique, and case series describing the consecutive first 77 patients to undergo transoral chondrolaryngoplasty (TCLP) at a quaternary transgender referral center. Results: Between November 2019 and April 2022, 77 patients underwent the novel surgery of TCLP. Median follow-up was 8.74 months (range: 1-30 months). Four patients suffered surgical complications (two laryngotomy, two skin necrosis), and three patients requested revision surgery. Conclusions and Relevance: TCLP is reported in the largest published series to date offering hidden incision for gender-affirming care. With further prospective outcome investigations, TCLP may prove to be a reliable approach of performing chondrolaryngoplasty while avoiding visible neck incisions.
Exposure to organochlorine pesticides (OCPs) and polychlorinated biphenyls (PCBs) has been reported to be associated with renal impairment and chronic kidney disease (CKD). Nevertheless, the research results thus far have exhibited inconsistency, and the effect of lifestyle on their association is not clear. In this study, we assessed the correlation between serum OCPs/PCBs and CKD and renal function indicators including estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (ACR) among 1721 Chinese adults. In order to further investigate the potential impact of lifestyle, we conducted joint associations of lifestyle and OCPs/PCBs on CKD. We found a negative correlation between p,p'-DDE and eGFR, while logistic regression results showed a positive correlation between PCB-153 and CKD (OR, 1.92; 95% CI, 1.21, 3.06). Quantile g-computation regression analyses showed that the association between co-exposure to OCPs/PCBs and CKD was not significant, but p,p'-DDE and PCB-153 were the main contributors to the negative and positive co-exposure effects of eGFR and CKD, respectively, which is consistent with the regression results. Participants with both relatively high PCB-153 exposure and an unhealthy lifestyle had the highest risk of CKD, in the joint association analysis. The observed associations were generally supported by the FAS-eGFR method. Our research findings suggest that exposure to OCPs/PCBs may be associated with decreased eGFR and increased prevalence of CKD in humans, and a healthy lifestyle can to some extent alleviate the adverse association between PCB-153 exposure and CKD.
Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
Dolasetron mesylate and its active metabolite, hydrodolasetron (MDL 74,156), are selective serotonin 5-HT3 receptor antagonists not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex.

In healthy volunteers (N=64), dolasetron mesylate in single intravenous doses up to 5 mg/kg produced no effect on pupil size or meaningful changes in EEG tracings. Results from neuropsychiatric tests revealed that dolasetron mesylate did not alter mood or concentration. Multiple daily doses of dolasetron have had no effect on colonic transit in humans. Dolasetron has no effect on plasma prolactin concentrations.
General 

This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, methylergonovine maleate should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.

Caution should be exercised in the presence of impaired hepatic or renal function. 

Breast-feeding 

Mothers should not breast-feed during treatment with methylergonovine maleate. Milk secreted during this period should be discarded. Methylergonovine maleate may produce adverse effects in the breast-feeding infant. Methylergonovine maleate may also reduce the yield of breast milk. Mothers should wait at least 12 hours after administration of the last dose of methylergonovine maleate before initiating or resuming breast feeding. 

Coronary artery disease 

Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. 

Medication errors

Inadvertent administration of methylergonovine maleate to newborn infants has been reported. In these cases of inadvertent neonatal exposure, symptoms such as respiratory depression, convulsions, cyanosis and oliguria have been reported. Usual treatment is symptomatic. However, in severe cases, respiratory and cardiovascular support is required. 

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. Due to the potential for accidental neonatal exposure, methylergonovine maleate injection should be stored separately from medications intended for neonatal administration.
BACKGROUND AND OBJECTIVES: Obstetric haemorrhage is the leading cause of maternal morbidity and mortality worldwide. We aimed to estimate the economic cost of Major Obstetric Haemorrhage (MOH) and the cost of therapeutic blood components used in the management of MOH in Ireland.
MATERIALS AND METHODS: We performed a nationwide cross-sectional study utilising top-down and bottom-up costing methods on women who experienced MOH during the years 2011-2013. Women with MOH were allocated to Diagnostic Related Groups (DRGs) based on the approach to MOH management (MOH group). The total number of blood components used for MOH treatment and the corresponding costs were recorded. A control group representative of a MOH-free maternity population was designed with predicted costs. All costs were expressed in Euro (€) using 2022 prices and the incremental cost of MOH to maternity costs was calculated. Cost contributions are expressed as percentages from the estimated total cost.
RESULTS: A total of 447 MOH cases were suitable for sorting into DRGs. The estimated total cost of managing women who experienced MOH is approximately €3.2 million. The incremental cost of MOH is estimated as €1.87 million. The estimated total cost of blood components used in MOH management was €1.08 million and was based on an estimated total of 3997 products transfused. Red blood cell transfusions accounted for the highest contribution (20.22%) to MOH total cost estimates compared to other blood components.
CONCLUSIONS: The total cost of caring for women with MOH in Ireland was approximately €3.2 million with blood component transfusions accounting for between one third and one half of the cost.
EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
Physicians use a PCE calculator to calculate the 10 year ASCVD risk. This approach aligns with current clinical guidelines to assist in decision-making.
Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
A method for providing a consumer with the ability to access and collect health records associated with the consumer through use of a consumer account is disclosed. A destination address individually associated with the consumer account for receiving communications from at least one healthcare providers is assigned. Access information is associated with the consumer account for the consumer to use to access a secure web site. A communication is received from one of the at least one health care providers. The communication is directed to the destination address and comprises a health record associated with the consumer for which the consumer has requested and given permission to the healthcare provider to send. A representation of the health record is stored. The consumer is provided with secure access to the web site using the access information and is provided on the web site an interface to the health records of the consumer for the consumer to use.
The present invention relates to a composition for use as pre-dipping and post-dipping for controlling mastitis in bovine animals. The composition comprises at least one water-soluble organic zinc salt having biocidal properties, wherein the concentration of zinc ions ranges between 5,000 and 60,000 ppm. Organic zinc salts are degradable, less irritating for the cow's nipple, improves skin condition, have an anti-inflammatory effect, accelerate wound healing processes and eliminate bacteria and fungi. Organic zinc salts are selected from: gluconate, lactate, glycinate, lysinate, citrate trihydrate, picolinate and acetate. Optionally, zinc sulphate monohydrate can be added in a concentration of less than 1.5% of the final product. The viscosity of the spray composition must be between 3 to 5 centipoise at room temperature. Additionally, the composition does not have corrosive activity in metals and non-metals.
NEW MATERIAL:To benzo[h]cinnoline derivative of formula I (X and Y are H, halogen, CF3, OH, alkyl, alkoxy, amino, alkanoylamido, nitro, cyano or alkanoyl; Ar is phenyl r pyridyl which may have one or more substituent groups selected from halogen, CF3, OH, alkyl alkoxy, amino, alkanoylamide, nitro and cyano). EXAMPLE:9-Chloro-2-phenyl-5,6-dihydrobenzo[cinnolin-3(2H)-one. USE:Agent for neutralizing overdoes antianxiety agent. An antianxiety agent, an antithrombotic agent, and diuretic hypotensor. The compound is advantageous as an antianxiety agent since it has no sedative effect. PREPARATION:The compound of formula I can be prepared e.g. by reacting the compound of formula II (R is H or alkyl) with the hydrazine derivative of formula ArNHNH2 or its acid addition salt, and cyclizing the resultant compound of formula III.
Support as usual comprise a possibility for informal caregivers to contact a specified nurse with expertise in head and neck , at the head and neck or oncology clinic, to ask for support. Healthcare counsellors at the clinics is also available for ICs on request. Group support providing emotional and social support for ICs to patients with various cancer diagnoses may also be arranged at the clinics occasionally. Also, the Swedish healthcare is always responsible for recognizing the need for support for children (\< 18 years) of patients with cancer.
PET studies have demonstrated a therapeutic window of dopamine D2 receptor occupancy (60-80%) in patients with schizophrenia. This observation has been used to predict the therapeutic dose range. Ziprasidone is recommended to be dosed twice daily, based on a knowledge of its half life in plasma level (5-10 hours). However, the plasma kinetics do not always mirror the central kinetics. Antipsychotics with a high-affinity at D2 receptors like risperidone attach for a relatively long time to their binding sites even after plasma levels declined. Based on this observation, another antipsychotic with a similar high-affinity at D2 receptors, ziprasidone, would also be expected to keep a sufficiently high D2 receptor occupancy even 24 hours after the last dose. Given \>60% D2 occupancy is required to maximize chance of therapeutic efficacy, it would be valuable to assess the D2 receptor occupancy 24 hours postdose to predict the therapeutic effects of once-daily regimen.

To date, there is no published report to examine D2 receptor occupancy of ziprasidone 24 hours after the last dose in patients with schizophrenia. This study will provide information on 24-hour time course of D2 occupancy of this drug, with which the dissociation between peripheral and central kinetics of this drug will be discussed. The results of this study will also test the feasibility of once daily dosing of ziprasidone, which will directly serve to guide physicians in clinical practice. Furthermore, the findings of this study will elucidate the relationship between D2 receptor occupancy and long-term outcome.

The primary objective to determine the difference in dopamine D2 occupancy of ziprasidone at expected peak plasma levels (6 hours) and 12 and 24 hours postdose. The secondary objectives are to compare ED50 (the plasma levels of ziprasidone resulting in 50% maximal receptor occupancy) 24 hours postdose with those 6 and 12 hours postdose.

Male or female patients aged 18-60 years suffering from schizophrenia or schizoaffective disorder will be eligible to participate in this study (Visit 1). Following the baseline clinical assessments (Visit 2), previous antipsychotics will be discontinued while initiating ziprasidone at 20mg BID and subsequently increasing the dose to 60mg BID (Visit 2-4). For patients already treated with ziprasidone 60 mg BID, no titration will be necessary. If patients are on a lower dose, they will only be included in the study if the treating clinician recommends an increase of the dose to 60 mg BID. Participants will undergo a total of 3 raclopride PET scans (6, 12, and 24 hours postdose) (Visits 5-7) after they have been on ziprasidone for at least 14 days. Psychopathology and side effects will also be assessed on these PET visits. MRI scan will be completed when possible (Visit 8). In the subsequent 6-month follow-up phase (Visit 9-17), participants will have clinical assessments biweekly in the first 3 months and monthly in the following three months. The dose will be titrated according to clinical response and tolerability in an open-labeled manner to a maximum dose of 80 mg BID.
An aqueous, antiseptic, iodophor solution is provided containing iodine, a water soluble iodide salt or hydriotic acid, polyvinyl alcohol and boric acid. The iodophor solution may be employed to sterilize a broad range of animate and inanimate objects, including contact lenses. Additionally, the iodophor solution, or similar iodophor solutions which do not contain boric acid, may be employed in visual temperature sensing devices. The visual temperature sensing devices comprise a transparent vessel containing the iodophor solution. Also disclosed is an aqueous solution for dissipating, at a controlled rate, available iodine contained in an iodophor. The aqueous dissipating solution contains sorbic acid or soluble salts thereof and ethylenediaminetetraacetic acid or soluble salts thereof.
Paclitaxel (PTX) is capable of aggravating radiation-induced pulmonary fibrosis (RIPF), but the mechanism is unknown. Spry2 is a negative regulator of receptor tyrosine kinase-related Ras/Raf/extracellular signal regulated kinase (ERK) pathway. This experiment was aimed at exploring whether the aggravation of RIPF by PTX is related to Spry2. The RIPF model was established with C57BL/6 mice by thoracic irradiation, and PTX was administered concurrently. Western blot was used to detect the expression level of ERK signaling molecules and the distribution of Spry2 in the plasma membrane/cytoplasm. Co-immunoprecipitation (co-IP) and immunofluorescence were used to observe the colocalization of Spry2 with the plasma membrane and tubulin. The results showed that PTX-concurrent radiotherapy could aggravate fibrotic lesions in RIPF, downregulate the content of membrane Spry2, and upregulate the levels of p-c-Raf and p-ERK in lung tissue. It was found that knockdown of Spry2 in fibroblast abolished the upregulation of p-c-Raf and p-ERK by PTX. Both co-IP results and immunofluorescence staining showed that PTX increased the binding of Spry2 to tubulin, and microtubule depolymerizing agents could abolish PTX's inhibition of Spry2 membrane distribution and inhibit PTX's upregulation of Raf/ERK signaling. Both nintedanib and ERK inhibitor were effective in relieving PTX-exacerbated RIPF. Taken together, the mechanism of PTX's aggravating RIPF was related to its ability to enhance Spry2's binding to tubulin, thus attenuating Spry2's negative regulation on Raf/ERK pathway. SIGNIFICANCE STATEMENT: This study revealed that paclitaxel (PTX) concurrent radiation therapy exacerbates radiation-induced pulmonary fibrosis during the treatment of thoracic tumors, which is associated with PTX restraining Spry2 and upregulating the Raf/extracellular signal regulated kinase signaling pathway, and provided drug targets for mitigating this complication.
Participants will receive pemetrexed 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
BACKGROUND: Cancer-associated cachexia (CAC) arises from malignant tumors and leads to a debilitating wasting syndrome. In the pathophysiology of CAC, the depletion of fat plays an important role. The mechanisms of CAC-induced fat loss include the enhancement of lipolysis, inhibition of lipogenesis, and browning of white adipose tissue (WAT). However, few lipid-metabolic enzymes have been reported to be involved in CAC. This study hypothesized that ELOVL6, a critical enzyme for the elongation of fatty acids, may be involved in fat loss in CAC.
METHODS: Transcriptome sequencing technology was used to identify CAC-related genes in the WAT of a CAC rodent model. Then, the expression level of ELOVL6 and the fatty acid composition were analyzed in a large clinical sample. Elovl6 was knocked down by siRNA in 3T3-L1 mouse preadipocytes to compare with wild-type 3T3-L1 cells treated with tumor cell conditioned medium.
RESULTS: In the WAT of patients with CAC, a significant decrease in the expression of ELOVL6 was found, which was linearly correlated with the extent of body mass reduction. Gas chromatographic analysis revealed an increase in palmitic acid (C16:0) and a decrease in linoleic acid (C18:2n-6) in these tissue samples. After treatment with tumor cell-conditioned medium, 3T3-L1 mouse preadipocytes showed a decrease in Elovl6 expression, and Elovl6-knockdown cells exhibited a reduction in preadipocyte differentiation and lipogenesis. Similarly, the knockdown of Elovl6 in 3T3-L1 cells resulted in a significant increase in palmitic acid (C16:0) and a marked decrease in oleic acid (C18:1n-9) content.
CONCLUSION: Overall, the expression of ELOVL6 was decreased in the WAT of CAC patients. Decreased expression of ELOVL6 might induce fat loss in CAC patients by potentially altering the fatty acid composition of adipocytes. These findings suggest that ELOVL6 may be used as a valuable biomarker for the early diagnosis of CAC and may hold promise as a target for future therapies.
OBJECTIVES: I. Compare the bone metastases free and overall survival in patients with asymptomatic recurrent prostate cancer treated with zoledronate vs placebo at different time points. II. Compare the time to first skeletal related events (pathological fractures, surgery to prevent or treat pathological fractures, spinal cord compression, and radiotherapy to bone) and skeletal morbidity rate in patients treated with these 2 regimens. III. Assess quality of life and pain in these patients treated with these 2 regimens.

OUTLINE: This is a randomized, double blind, placebo controlled, open label, multicenter study. Patients are stratified by prior local treatment (noncurative vs curative) and time interval between surgical castration or initiation of LHRH agonists and trial entry (less than 1 year vs 1-2 years vs greater than 2 years). Patients are randomized to 1 of 2 treatment arms: Arm I: Patients receive zoledronate IV over 15 minutes on day 1. Arm II: Patients receive placebo IV over 15 minutes on day 1. Both arms: Treatment repeats every 4 weeks in the absence of documented bone metastasis, disease progression, or unacceptable toxicity. All patients with documented bone metastases receive zoledronate as in arm I through year 4. All patients receive oral calcium and oral vitamin D daily. Patients who received LHRH agonists instead of surgical castration prior to study continue LHRH agonist therapy during study. Quality of life and pain are assessed before each treatment. Patients are followed every 6 months.

PROJECTED ACCRUAL: A total of 500 patients (250 per arm) will be accrued for this study.